Why Is SGHT Stock Rising After Hours? Sight Sciences Gains After Q2 Earnings Beat

Sight Sciences (SGHT) shares rose 12.25% in after-hours trading on Wednesday after the company reported second-quarter revenue that beat expectations and raised its full-year guidance. A 704% surge in Interventional Dry Eye revenue and recent FDA clearance for the OMNI Ultra Surgical System added to the positive sentiment.

What Did Sight Sciences Report?

Sight Sciences reported second-quarter 2026 revenue of $23.4 million, a 20% increase from the prior-year period. Surgical Glaucoma revenue came in at $20.7 million, up 8% year-over-year, while Interventional Dry Eye revenue surged 704% to a record $2.7 million.

The net loss narrowed to $4.4 million, or $0.08 per share, from $11.9 million in the same quarter last year. Operating expenses fell 11% to $25.3 million, and cash usage dropped 28% to $5.2 million. The company ended the quarter with $79.8 million in cash and $40.0 million in long-term debt.

Management raised full-year 2026 revenue guidance to a range of $88 million to $92 million and lowered its adjusted operating expense guidance to $92 million to $94 million.

Separately, the company highlighted two regulatory developments. On August 4, Sight Sciences received FDA 510(k) clearance for the OMNI Ultra Surgical System, the first FDA-cleared MIGS device enabling circumferential canaloplasty in a single pass. Aetna also updated its Glaucoma Surgery Policy to recognize the OMNI and SION surgical systems as medically necessary for mild-to-moderate open-angle glaucoma, covering approximately 25 million commercial lives retroactive to July 14.

Why Did Investors React?

The magnitude of the post-market move reflects the combination of an earnings beat, a guidance raise, and two regulatory catalysts landing in the same 24-hour window.

The 704% surge in Interventional Dry Eye revenue signals that Sight Sciences is scaling a second growth franchise beyond its core Surgical Glaucoma business. At $2.7 million in quarterly revenue, the IDE segment is still small, but the growth rate suggests the company's TearCare and related dry eye technologies are gaining commercial traction.

The raised full-year revenue guidance of $88 million to $92 million implies management sees the momentum carrying into the second half of the year. Combined with narrowing losses and declining cash usage, the results point toward improving operating leverage.

The FDA clearance for the OMNI Ultra and the Aetna coverage expansion provide additional near-term catalysts. The OMNI Ultra's single-pass circumferential canaloplasty capability is a technical advance in the MIGS category, and the company plans a U.S. commercial launch in the fourth quarter. The Aetna policy update broadens the reimbursed patient base for the company's flagship glaucoma procedures.

What Comes Next?

The stock's after-hours movement will be tested when regular trading resumes. Post-market liquidity is thinner than during normal market hours, and the move may be amplified as a result — investors will watch whether institutional participation confirms the direction.

The earnings conference call may provide additional detail on the guidance raise, including segment-level assumptions and the expected contribution from the OMNI Ultra launch. The U.S. commercial rollout of the OMNI Ultra in the fourth quarter will be a key milestone to track, as will the pace at which the Aetna coverage expansion translates into higher procedure volumes.

As a small-cap medical device company, Sight Sciences faces execution risk in commercializing a new surgical system while sustaining the growth trajectory of its dry eye franchise. The regular session will show whether the market's initial reaction holds up under broader participation.